



ISICEM 2014: CytoSorbents to Sponsor CytoSorb® Research Symposium



CytoSorbents Corporation, a critical care immunotherapy company using blood purification to treat life-threatening illnesses in the intensive care unit, announced that it will sponsor a research symposium entitled:

"SIRS and SEPSIS – New Therapy with CytoSorb®"

at the 34th International Symposium on Intensive Care and Emergency Medicine (ISICEM 2014) in Brussels, Belgium next week. The program is scheduled for Wednesday, March 19, 2014 from 6:15 – 7:45 PM in the ARC room of the Square – Brussels Meeting Center. Refreshments will be served.

Distinguished physicians will discuss the application of CytoSorb® extracorporeal cytokine reduction in sepsis and other inflammatory conditions, such as cardiac surgery.

- Dr. Herwig Gerlach (Berlin, Germany): "Overshooting the inflammatory response – The Root of all Evil?"
- Dr. John Kellum (Pittsburgh, USA): "Blood purification in SIRS and Sepsis: A new paradigm"
- Dr. Michael Quintel (Gottingen, Germany): "Clinical Experience: Severe sepsis/ septic shock and CytoSorb® therapy"
- Dr. Karl Trager (Ulm, Germany): "Clinical Experience: Post-Cardiopulmonary Bypass SIRS and CytoSorb® therapy."

In addition, attendees can visit CytoSorbents' exhibit booth in the Silver Foyer, Booth S.01 from March 18-21, 2014 to learn more about CytoSorb® immunotherapy for critical illnesses and how, through cytokine reduction, it targets a reduction of the potentially deadly systemic inflammatory response syndrome (SIRS) in order to prevent or treat organ failure and improve clinical outcomes.

About CytoSorbents

CytoSorbents Corporation is a critical care focused immunotherapy company using blood purification to modulate inflammation -- with the goal of preventing or treating multiple organ failure in life-threatening illnesses.

Organ failure is the cause of nearly half of all deaths in the intensive care unit, with little to improve clinical outcome. CytoSorb®, the Company's flagship product, is approved in the European Union as a safe and effective extracorporeal cytokine filter, designed to reduce the "cytokine storm" that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma,

lung injury, and pancreatitis. These are conditions where the risk of death is extremely high, yet no effective treatments exist.

CytoSorbents' purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. CytoSorbents has numerous products under development based upon this unique blood purification technology, protected by 32 issued US patents and multiple applications pending, including HemoDefend™, ContrastSorb, DrugSorb, and others.

Source: [CytoSorbents](#)

14 March 2014

Published on : Fri, 14 Mar 2014